KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$3.7 billion.

  • Nektar Therapeutics' Retained Earnings fell 335.05% to -$3.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.7 billion, marking a year-over-year decrease of 335.05%. This contributed to the annual value of -$3.6 billion for FY2024, which is 342.11% down from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Retained Earnings is -$3.7 billion, which was down 335.05% from -$3.7 billion recorded in Q2 2025.
  • Nektar Therapeutics' Retained Earnings' 5-year high stood at -$2.4 billion during Q1 2021, with a 5-year trough of -$3.7 billion in Q3 2025.
  • Over the past 5 years, Nektar Therapeutics' median Retained Earnings value was -$3.4 billion (recorded in 2023), while the average stood at -$3.3 billion.
  • As far as peak fluctuations go, Nektar Therapeutics' Retained Earnings tumbled by 2276.48% in 2021, and later tumbled by 335.05% in 2025.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Retained Earnings stood at -$2.8 billion in 2021, then fell by 13.0% to -$3.2 billion in 2022, then dropped by 8.62% to -$3.5 billion in 2023, then fell by 3.42% to -$3.6 billion in 2024, then fell by 3.56% to -$3.7 billion in 2025.
  • Its last three reported values are -$3.7 billion in Q3 2025, -$3.7 billion for Q2 2025, and -$3.6 billion during Q1 2025.